Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation

Haematologica

Volumn 93, Issue 6, 2008, Pages 885-891

  Navarro, Silvia ^a   Medina, Pilar ^a   Mira, Yolanda ^a   Estellés, Amparo ^a   Villa, Piedad ^a   Ferrando, Fernando ^a   Vayá, Amparo ^a   Bertina, Rogier M ^b   España, Francisco ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activated protein C; Endothelial protein C receptor; Prothrombin G20210A mutation; Prothrombin level; Venous thromboembolism

Indexed keywords

ENDOTHELIAL PROTEIN C RECEPTOR; PROTHROMBIN;

ADULT; ALLELE; ARTICLE; BIVARIATE ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOTHELIAL PROTEIN C RECEPTOR GENE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

ADULT; AGE OF ONSET; ALLELES; ANTIGENS, CD; FEMALE; HAPLOTYPES; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEIN C; PROTHROMBIN; RECEPTORS, CELL SURFACE; RISK; VENOUS THROMBOSIS;

EID: 44949100143     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12448     Document Type: Article

References (24)

1. Poort SR, Rosendaal FR, Reitsma PH, Bertina, RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
2. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418-22.
3. Castoldi E, Simioni P, Tormene D, Thomassen MCLGD, Spiezia L, Gavasso S, et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost 2007;5:971-9.
4. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
5. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thromb Haemost 2004;2:119-27.
6. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007;92:1107-14.
7. Tirado I, Mateo J, Soria JM, Oliver A, Borrell M, Coll I, et al. Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies. Haematologica 2001;86:1200-8.
8. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-16.
9. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscl Thromb Vasc Biol 1999;19:700-3.
10. Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004;89:201-6.
11. Gisslinger H, Mullner M, Pabinger I, Heis-Vahidi-Fard N, Gisslinger B, Brichta A, et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica 2005;90:408-10.
12. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992;12:135-45.
13. Qu D, Wang Y, Esmon NL, Esmon CT. Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-a converting enzyme/ADAM17. J Thromb Haemost 2007;5:395-402.
14. Saposnik B, Reny JL, Gausem P, Emmerich J, Aiach M, Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004;103:1311-8.
15. Medina P, Navarro S, Estellés A, Vayá A, Woodhams B, Mira Y, et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels and thrombotic risk. Thromb Haemost 2004;91:905-11.
16. Uitte de Willige S, van Marion V, Rosendaal FR, Vos HL, de Visser MCH, Bertina RM. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost 2004;2:1305-10.
17. Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mollica J, Fukudome K, Esmon CT. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem 1996;271:17499-503.
18. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997;100:411-8.
19. Medina P, Navarro S, Estellés A, Vayá A, Bertina RM, España F. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. Thromb Haemost 2005;94:389-94.
20. España F, Zuazu I, Vicente V, Estellés A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays. Enzyme levels are proportional to total protein C levels. Thromb Haemost 1996;75:56-61.
21. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coag Fibrinol 1995;6:245-7.
22. España F, Vayá A, Mira Y, Medina P, Estellés A, Villa P, et al. Low level of circulating activated protein C is a risk factor for venous thrombosis. Thromb Haemost 2001;86:1368-73.
23. Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 1999;94:3839-46.
24. Saposnik B, Lesteven E, Lokajczyk A, Emmerich J, Esmon CT, Aiach M, et al. An abnormal mRNA splicing is associated with the A3 haplotype of the EPCR gene PROCR: A possible new contributor to plasma soluble EPCR levels. J Thromb Haemost 5 Supplement 2: O-W-091.